Department of the Army, DoD.
In accordance with 35 U.S.C. 209(e) and 37 CFR 404.7(a)(I)(i), announcement is made of the intent to grant an exclusive, royalty-bearing, revocable license to U.S. Patent No. 6,451,309 entitled “Prophylactic and Therapeutic Monoclonal Antibodies,” issued September 17, 2002; and U.S. Patent No. 6,620,412 entitled, “Prophylactic and Therapeutic Monoclonal Antibodies,” issued September 16, 2003, which is a continuation of U.S. Patent No. 6,451,309, and foreign rights to BioFactura, Inc., with its principal place of business at 9700 Great Seneca Highway, Rockville, Maryland 20850.
Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702-5012.Start Further Info
FOR FURTHER INFORMATION CONTACT:
For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619-6664. For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808, both at telefax (301) 619-5034.End Further Info End Preamble Start Supplemental Information
Anyone wishing to object to the grant of this license can file written objections along with supporting evidence, if any, 15 days from the date of this publication. Written objections are to be filed with the Command Judge Advocate (see ADDRESSES).Start Signature
Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. E8-18705 Filed 8-12-08; 8:45 am]
BILLING CODE 3710-08-P